# Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

> **NCT00112619** · PHASE1 · TERMINATED · sponsor: **Pediatric Brain Tumor Consortium** · enrollment: 19 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors
- Carcinoma of Unknown Primary
- Leukemia
- Lymphoma
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00112619
- **Lead sponsor:** Pediatric Brain Tumor Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** 2010-08
- **Final completion:** —
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Slow accrual and company withdrawing support to supply the drug
- **Last updated:** 2011-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00112619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00112619, "Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00112619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*